Ligand Pharm Cmn (LGND) 114.37 $LGND 7 Profitable

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ligand Pharm Cmn (LGND) 114.37 $LGND

7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 47.52 (+0.19), JNJ: 116.97 (+0.51), PFE: 34.40 (-0.07), LGND: 114.37 (+0.54), BMY: 72.26 (-0.05), AMPH: 15.90 (+0.31)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.45 (unch), RTRX: 18.28 (-0.20), AVEO: 0.95 (-0.04), SNSS: 0.57 (+0.01), LGND: 114.37 (+0.54), BIND: 0.41 (unch), ACOR: 25.82 (+0.55)

SmarTrend Watching for Potential Pullback in Shares of Ligand Pharmaceuticals After 1.08% Gain
Comtex SmarTrend(R) - Wed Jun 15, 3:13PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.62 to a high of $117.18. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.07 on volume of 107,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 114.37 (+0.54)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.22 (+0.02), BIIB: 237.20 (+2.60), IDRA: 1.51 (+0.03), RTRX: 18.28 (-0.20), LGND: 114.37 (+0.54), ACOR: 25.82 (+0.55)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 48.78 (+0.61), OMED: 12.76 (+0.15), LGND: 114.37 (+0.54), ANIK: 50.74 (+0.47)

Ligand (LGND) Beats Q1 Earnings and Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed May 04, 6:56AM CDT
Ligand???s first-quarter 2016 earnings surpassed expectations by a wide margin.
LGND: 114.37 (+0.54)

Ligand tops 1Q revenue forecasts
Automated Insights - Wed May 04, 5:21AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Wednesday reported first-quarter earnings of $6.6 million.
LGND: 114.37 (+0.54)

Ligand Reports First Quarter 2016 Financial Results
BusinessWire - Wed May 04, 5:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.
LGND: 114.37 (+0.54)

Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix(R) Cardiovascular for $17.5 Million
BusinessWire - Wed May 04, 4:59AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to multiple programs owned by CorMatrix(R). Ligand will pay $17.5 million and in return will receive a portion of revenue (synthetic royalty) from CorMatrix's existing marketed products and will have the right to receive future synthetic royalties from potential future products. CorMatrix's products are medical devices that are designed to permit the development and regrowth of human tissue. This transaction will be immediately accretive to Ligand and represents Ligand's entry into the field of medical devices.
LGND: 114.37 (+0.54)

Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 36.58 (+0.91), ECYT: 3.39 (+0.07), CLDX: 4.54 (+0.09), LGND: 114.37 (+0.54), AMGN: 151.22 (+1.41), IONS: 22.95 (+0.36), REGN: 355.31 (+3.39)

Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 114.37 (+0.54), SPPI: 6.84 (+0.04), BIND: 0.41 (unch), FOLD: 5.69 (-0.05)

Ligand Pharmaceuticals Has Returned 34.5% Since SmarTrend Recommendation (LGND)
Comtex SmarTrend(R) - Thu Apr 28, 1:42PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 34.48% as of today's recent price of $125.11.
LGND: 114.37 (+0.54)

Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences
BusinessWire - Fri Apr 22, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces plans to report first quarter 2016 financial results prior to the opening of trading on May 4, 2016. Ligand's CEO John Higgins and CFO Matt Korenberg will discuss the quarterly results later that day during Ligand's presentation at Deutsche Bank's 41st Annual Healthcare Conference in Boston. The presentation will be webcast live and also will be archived.
LGND: 114.37 (+0.54)

37.3% Return Seen to Date on SmarTrend Ligand Pharmaceuticals Call (LGND)
Comtex SmarTrend(R) - Wed Apr 20, 12:50PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 37.30% as of today's recent price of $127.73.
LGND: 114.37 (+0.54)

Ligand Pharmaceuticals Has Returned 26.6% Since SmarTrend Recommendation (LGND)
Comtex SmarTrend(R) - Wed Apr 13, 12:22AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 26.64% as of today's recent price of $117.81.
LGND: 114.37 (+0.54)

Will Ligand Pharmaceuticals (LGND) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:27AM CDT
Ligand Pharmaceuticals Inc. (LGND) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
LGND: 114.37 (+0.54)

Revolade(R) Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
BusinessWire - Thu Apr 07, 8:00AM CDT
--EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies
LGND: 114.37 (+0.54)

Uptrend Call Working As Ligand Pharmaceuticals Stock Rises 20.2% (LGND)
Comtex SmarTrend(R) - Tue Apr 05, 1:27PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 1 month, Ligand Pharmaceuticals has returned 20.16% as of today's recent price of $111.78.
LGND: 114.37 (+0.54)

After Yesterday's Rally of 3.23% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Mar 31, 2:49PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $105.15 to a high of $108.79. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $107.49 on volume of 177,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 114.37 (+0.54)

Ligand Enters Into OmniAb(R) Platform License Agreement With ABBA Therapeutics
BusinessWire - Mon Mar 28, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing innovative immuno-oncology therapies. Under the license, ABBA will be able to use the OmniRat(R), OmniMouse(R) and OmniFlic(R) platforms to generate fully human mono- and bispecific antibodies. Ligand is to receive an initial access payment, and will be eligible to receive clinical milestone payments and royalties for each successful OmniAb antibody. ABBA will be responsible for all costs related to the program.
LGND: 114.37 (+0.54)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 640

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Partnership Boosts Clinical Trials with AI Insights

Updated Category News Views 138

Transforming Clinical Trials Through AI Collaboration In a groundbreaking announcement, NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an innovative leader in artificial intelligence, has entered into a significant partnership with Pentara Corporation, a trusted name in the pharmaceutical data analytics sector. This collaboration aims to...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 414

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Minerals Technologies Enhances Pet Care Operations for Future Growth

Updated Category News Views 95

Minerals Technologies' Strategic Expansion in Pet Care Sector Minerals Technologies Inc. (NYSE: MTX) is making substantial strides to expand its operations in the pet care sector, particularly focusing on its SIVO™ brand of cat litter. This global leader in specialty minerals is undergoing transformative upgrades in its facilities across various countries, responding to...

Continue Reading
Insight into Latest Trading Activities of Treatt plc

Updated Category News Views 194

Key Information about Treatt plc Trading FORM 8.5 (EPT/RI) Public Disclosure by an Exempt Principal Trader in Client-Serving Capacity Rule 8.5 of the Takeover Code (the "Code") Essential Details (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree related to this form: Treatt plc (c) Connection of Exempt Principal Trader t

Continue Reading
Breeze Holdings Forms Strategic Alliance with YD Biopharma

Updated Category News Views 87

Breeze Holdings and YD Biopharma Unite Breeze Holdings Acquisition Corp. is thrilled to share an important milestone in its journey. The company has reached a definitive agreement to merge with YD Biopharma Limited. This isn't just any business deal; it marks a significant move toward advancements in cancer prevention and diagnostics. Discovering YD Biopharma's Purpose YD...

Continue Reading